ReviewBiomarker research2019
Targeted therapies for myeloproliferative neoplasms.
Review in Biomarker research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Longitudinal prospective analysis of organ stiffness and cardiac function in patients with myelofibrosis treated with ruxolitinib type of study: Prospective single-center cohort study.Therapeutic advances in hematology · 2026Article
- Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.Journal of medicinal chemistry · 2024Article
- JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma.Science advances · 2023Article
- Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms.World journal of hepatology · 2023Review
- Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations.BMC genomic data · 2023Article
- New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.Cell chemical biology · 2023Article
- Mutations, inflammation and phenotype of myeloproliferative neoplasms.Frontiers in oncology · 2023Review
- Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.The oncologist · 2022Article
- Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2Blood cancer journal · 2022Article
- Review
- Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome.Experimental hematology & oncology · 2021Article
- Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.Journal of hematology & oncology · 2021Review
- Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.Hematological oncology · 2020Review
- Article
- CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.Journal of hematology & oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The discovery of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.